Pay in 4 interest-free payments of $7.09 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Read our storage guide
What Studies Have NOT Demonstrated in Humans Despite community claims, no controlled human trial has demonstrated: A specific body fat percentage reduction attributable to LR3 IGF-1 cycling A specific lean mass gain figure for the standard 10-day-on / 4-week-off pattern Cardiovascular safety endpoints across repeated cycles Long-term cancer-incidence data for cycled LR3 IGF-1 use Epidemiological data on chronically elevated endogenous IGF-1 has raised theoretical cancer concerns (Yoshida & Delafontaine, 2020), and that concern is one reason community protocols favor short, spaced cycles rather than continuous use
TB-500, a synthetic fragment of thymosin beta-4, has been investigated for its role in actin regulation, cell migration, and processes involved in tissue regeneration and wound healing
Cejas P, Garcia-Cabezas MA, Casado E, Belda-Iniesta C, De Castro J, Fresno JA, Sereno M, Barriuso J, Espinosa E, Zamora P, et al
Martchenko A, Oh RH, Wheeler SE, Gurges P, Chalmers JA, Brubaker PL
Updated May 19, 2026
US$ 29.39
US$ 23.20
US$ 23.35
US$ 28.81
US$ 25.80
US$ 23.20
US$ 25.35
US$ 22.01
US$ 21.31
US$ 24.92
US$ 22.81
US$ 25.20
US$ 29.26
US$ 21.69
US$ 27.54
US$ 29.46
